The effect of magnetic resonance imaging localisation of prostate cancer on transrectal ultrasound biopsy detection rate

Not Applicable

Completed

• Conditions: Prostate cancer; Cancer; Malignant neoplasm of prostate

• Registration Number: ISRCTN28276837
• Lead Sponsor: Department of Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2005-08-01
• Study Start: 2005-09-30
• Last Update Posted: 26 February 2018

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 122

Inclusion Criteria

All patients who are to have a transrectal ultrasound (TRUS) biopsy (on a Thursday) to confirm prostate cancer, with an intermediate PSA level (10-19 ng/ml), will be eligible for entry to the study. On average 8 patients undergo TRUS biopsy at Cookridge Hospital per week (divided between Tuesday and Thursday morning sessions). One MRI slot per week (Thursday morning) will be available for the study. All consenting patients will be randomised and one selected for the MRI cohort and all others will form the non-MRI cohort. Assuming at least 2 patients are recruited a week (50%) recruitment rate) the two cohorts (61 patients in each) will be recruited in 61 weeks.

Exclusion Criteria

1. Unwilling/unable to give informed consent
2. Significant claustrophobia
3. Contra indications to MRI: pacemaker, aneurysm clips, metallic foreign bodies in the eye

Study & Design

• Study Type: Interventional
• Study Design: Not specified